Last reviewed · How we verify
NCT04595032: MAMETIC
MAnagement of METastatic Disease in Campania (MAMETIC)
trial testing 3DCRT, IMRT, VMAT, SBRT in Metastatic Disease in 3,234 participants. Completed in 8 February 2024.
8 February 2024
Quick facts
| Lead sponsor | National Cancer Institute, Naples |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 3,234 |
| Start date | 11 September 2020 |
| Primary completion | 8 February 2024 |
| Estimated completion | 8 February 2024 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- 3DCRT, IMRT, VMAT, SBRT
Conditions studied
- Metastatic Disease — all drugs for Metastatic Disease →
Sponsor
National Cancer Institute, Naples
Who can join
18 and older, any sex, with Metastatic Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The MAMETIC Trial represents the first regional epidemiological study that aims to evaluate patients living in Campania with metastatic cancer, with the intent to detect different prevalence of tumors in the metastatic phase and evaluate the local response to the patient's request for assistance. Condition or disease: Metastatic disease Intervention/treatment: Radiation Treatment
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Management of Metastatic Disease in Campania (MAMETIC): An Observational Multicenter Retrospective and Prospective Trial on Palliative Radiotherapy in an Italian Region. Study Protocol.
Di Franco R, Cascella M, Fusco M, Borzillo V, et al · · 2022 · PMID 35422656 · DOI 10.2147/jpr.s336357 -
Management of Metastatic Disease in Campania (MAMETIC): Epidemiologic Data and Palliative Radiotherapy in an Italian Region. Study Protocol
FRANCO RD, Cascella M, Fusco M, Borzillo V, et al · · 2021 · DOI 10.21203/rs.3.rs-316250/v1 -
MA Nagement of METastatic Disease In Campania (MAMETIC): Epidemiologic Data and Palliative Radiotherapy in an Italian Region. Study Protocol
Franco RD, Cascella M, Fusco M, Borzillo V, et al · · 2021 · DOI 10.21203/rs.3.rs-216775/v1
Verify or expand the search:
- PubMed search for NCT04595032
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Metastatic Disease
Currently open trials in the same condition.
- NCT06856603 — OLIGO-10: Stereotactic Ablative Radiation Therapy for Metastatic Patients With 6 to 10 Metastatic Sites · Phase 2 · recruiting
Other National Cancer Institute, Naples trials
Trials by the same sponsor.
- NCT07459920 — Cannabis extrAct in Oncology Patients for the Treatment of TUmor Related Symptom Burden · Phase 2 · not yet recruiting
- NCT07302451 — REDI-CaP(Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients) · Phase 2 · active not recruiting
- NCT06714357 — ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer · Phase 2 · recruiting
- NCT06886282 — Spatial RadiomIcs and TRanscriptomics to the DIscovery of the Cross-link Between Colon Cancer and ChrOnic Kidney Disease · recruiting
- NCT06887244 — Effectiveness of Nurse Tele-consultation on the Quality of Elective Colonoscopy, Procedure-related Anxiety, and Financia · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04595032 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute, Naples
- Last refreshed: 7 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04595032.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing